Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NSDHL siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Inhalation, Intranasal, Topical, Oral, Parenteral
01
Overview
NSDHL siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of NAD(P)-dependent steroid dehydrogenase-like (NSDHL), an enzyme crucial to the cholesterol biosynthesis pathway. In preclinical studies, siRNA-mediated knockdown of NSDHL has been shown to inhibit the formation of tightly cohesive tumorspheres, reduce breast cancer stem cell (BCSC) populations, and suppress tumor initiation and growth in orthotopic breast cancer models. It is primarily utilized as a research-use-only (RUO) laboratory tool to investigate the role of cholesterol metabolism in cancer stemness and progression.
- Other names
- siNSDHLsiRNA targeting NSDHLsmall interfering RNA targeting NSDHL
02
Targets
GLI1NSDHL (Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating)TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB3 (Transforming growth factor beta 3)NSDHL (NAD(P)-dependent steroid dehydrogenase-like)
Beyond the preview
Go deeper on NSDHL siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NSDHL siRNA.